story of the week
Once-Weekly Insulin Icodec vs Once-Daily Insulin Glargine U100 in Individuals With Basal–Bolus Insulin-Treated Type 2 Diabetes
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial
Lancet 2023 May 05;[EPub Ahead of Print], C Mathieu, B Ásbjörnsdóttir, HS Bajaj, W Lane, ALSA Matos, S Murthy, K Stachlewska, J RosenstockFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.